CA
NZ
UK
AU
IND
US
Humacyte, Inc. is facing headwinds with a Q2 2026 net loss of $54.4 million as the company grapples with slower-than-expected adoption of its vascular conduit, Symvess. The management has attributed the sluggish uptake to a miscalculation regarding educational efforts necessary for its introduction. To …
Illumina (NASDAQ: ILMN), Inc. has entered into a $1 billion senior unsecured revolving credit facility, marking a significant enhancement to its financial strategies. This credit agreement provides the company with a solid platform to meet working capital demands and support general corporate activities. The …
Eikon Therapeutics, Inc. (NASDAQ: EIKN) has amended its corporate presentation as of August 13, 2026, offering critical insights into its clinical trial strategies and upcoming milestones. The updated materials underscore the company's strong pipeline aimed at addressing pressing medical needs across various fields, particularly …
Eikon Therapeutics, Inc. (NASDAQ: EIKN) has amended its corporate presentation as of August 13, 2026, offering critical insights into its clinical trial strategies and upcoming milestones. The updated materials underscore the company's strong pipeline aimed at addressing pressing medical needs across various fields, particularly …
Elutia Inc. (NASDAQ: ELUT) reported its second-quarter results, marking a period of substantial growth and strategic development. The results, issued on August 13, 2026, reveal a commitment to expanding its capability in drug-eluting biomatrix products. The announcement included plans to secure an additional $5 …
The announcement included key information regarding adjusted EBITDA, a non-GAAP financial measure designed to offer investors clearer insights into the company’s operational performance. By focusing on adjusted EBITDA, Eton aims to provideStakeholderswith a consistent basis for evaluating its performance across reporting periods.
Dare Bioscience, Inc. (NASDAQ: DARE) has released its quarterly results in a regulatory filing dated August 13, 2026. This update is a critical moment for the company, as it provides an overview of its financial performance and strategic direction. While specific figures are not …
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) reported a strategic credit facility valued at up to $200 million from Hercules Capital, along with an initial draw of $20 million. This funding provides critical financial flexibility as the company prepares for significant operational milestones.
Capricor Therapeutics (NASDAQ: CAPR) disclosed that Duchenne muscular dystrophy, a rare genetic disorder, impacts roughly 15,000 individuals across the United States. The company presented this patient‑population estimate as part of its quarterly results released on August 13, 2026, using the figure to underscore the …
CapsoVision, Inc (NASDAQ: CV). has announced a revenue increase of 10%, with total revenues climbing to $3.6 million in 2026. This growth marks a significant step forward for the company, even as it navigates ongoing profitability challenges.
Please wait processing your request...